Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 2 · 33.3%Low 0 · 0%Moderate 1 · 16.7%High 2 · 33.3%

Beta‐blockers vs placebo or no treatment

Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 245 participants
Very low

CHRONIC: Beta‐blockers vs placebo

Hyperkalaemia · heart failure with chronic kidney disease

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for heart failure in people with chronic kidney disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 74 participants
Very low

Angiotensin receptor blockers (ARBs) vs placebo or no treatment

Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor blockers (ARBs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 1.88 [1.07, 3.33]
2 studies · 7148 participants
High

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 2.11 [1.77, 2.52]
6 studies · 4291 participants
High

Angiotensin receptor neprilysin inhibitors (ARNIs) vs usual care

Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction

Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in hyperkalaemia Range of compared with usual care (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.88 [0.77, 1.01]
2 studies · 5054 participants
Moderate